First Time Loading...
G

Gemini Therapeutics Inc
NASDAQ:GMTX

Watchlist Manager
Gemini Therapeutics Inc
NASDAQ:GMTX
Watchlist
Price: 19.89 USD 47.33% Market Closed
Updated: May 14, 2024

Gemini Therapeutics Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gemini Therapeutics Inc
Income from Continuing Operations Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
G
Gemini Therapeutics Inc
NASDAQ:GMTX
Income from Continuing Operations
-$46.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$4.9B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$456m
CAGR 3-Years
19%
CAGR 5-Years
-40%
CAGR 10-Years
-21%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$3.8B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
$3.6B
CAGR 3-Years
10%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$3.9B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
26%

See Also

What is Gemini Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-46.8m USD

Based on the financial report for Dec 31, 2022, Gemini Therapeutics Inc's Income from Continuing Operations amounts to -46.8m USD.

What is Gemini Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 1Y
35%

Over the last year, the Income from Continuing Operations growth was 35%.